The clinicopathological and prognostic significance of PSMD14 in cancers based on bioinformatics and meta-analysis

Shu-Yi Dong ^1,2, Shuxin Ding ^1,2, Zhen Meng ^1,2

⁰Department of Oral & Maxillofacial Surgery, Liaocheng People's Hospital, Medical College of Liaocheng University, Liaocheng, Shandong, P. R. China.

Future Science Oa +

|

October 11, 2024

View abstract on PubMed

Summary

High PSMD14 expression indicates a poor prognosis in multiple cancers, correlating with advanced tumor features and reduced survival. This protein may serve as a valuable cancer biomarker.

Area Of Science

Oncology
Molecular Biology
Biomarker Discovery

Background

The proteasome subunit PSMD14 plays a role in cellular processes.
Its specific role and prognostic significance in various human cancers remain incompletely understood.

Purpose Of The Study

To investigate the clinicopathological features and prognostic value of PSMD14 in diverse cancer types.
To determine if PSMD14 expression can serve as a predictive biomarker for patient outcomes.

Main Methods

Systematic literature review of studies published until June 2023.
Analysis of survival data and clinicopathological characteristics from public databases.
Validation using The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) datasets.

Main Results

Eight studies encompassing seven cancer types revealed that elevated PSMD14 expression is associated with decreased overall survival and disease-free survival.
PSMD14 expression levels correlated with tumor size, differentiation status, and metastasis.
The study also explored the relationship between PSMD14 expression and the efficacy of chemotherapy drugs.

Conclusions

PSMD14 is a potential biomarker for predicting poor prognosis in several cancers.
Specific cancers where PSMD14 may be a prognostic indicator include lung cancer, head and neck squamous cell carcinoma, ovarian cancer, breast cancer, and hepatocellular carcinoma.

Keywords:

PSMD14 bioinformatical analysis cancer meta-analysis